Lonza Walkersville announced its new offering of Silensomes Human Liver Microsomes (HLM) products – pooled human liver microsomes for in vitro cytochrome P450 (CYP) phenotyping. CYP phenotyping is a regulatory requirement for new drug candidates to understand their metabolism and to predict drug-drug interactions.
Lonza Walkersville's new Silensomes HLM products provide researchers a fully characterized pre-made solution for CYP phenotyping, resulting in more consistent and reliable results.
Lonza's Silensomes HLM products include seven cryopreserved human liver microsomes pools that are each pre-treated with a mechanistic-based inhibitor targeting a single CYP enzyme. This chemical inactivation is mechanism-based and irreversible, giving researchers confidence that their results are accurate and reliable. Each of the seven CYP Silensomes HLM are packaged as Silensomes CYP Phenotyping Kits to include a production-matched control microsome that was treated the same way without the inhibitor. A panel consisting of all seven Silensomes HLM with a single matched control is also available.
This new product offering from Lonza is a result of the company's recent agreement with Biopredic International and strengthens Lonza's position as a leading supplier of ADME-Tox products for scientists working in drug development. The addition of Silensomes HLM products expands Lonza's extensive ADME-Tox portfolio, which includes fresh and cryopreserved human and animal primary hepatocytes, specialized media and cell culture systems.